- Home
- MFIN vs GLSI Comparison
MFIN vs GLSI Comparison
Compare MFIN & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFIN
- GLSI
- Stock Information
- Founded
- MFIN 1995
- GLSI 2006
- Country
- MFIN United States
- GLSI United States
- Employees
- MFIN N/A
- GLSI N/A
- Industry
- MFIN Finance: Consumer Services
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- MFIN Finance
- GLSI Health Care
- Exchange
- MFIN Nasdaq
- GLSI Nasdaq
- Market Cap
- MFIN 243.9M
- GLSI 149.5M
- IPO Year
- MFIN 1996
- GLSI 2020
- Fundamental
- Price
- MFIN $10.33
- GLSI $11.15
- Analyst Decision
- MFIN Strong Buy
- GLSI Strong Buy
- Analyst Count
- MFIN 1
- GLSI 1
- Target Price
- MFIN $12.00
- GLSI $39.00
- AVG Volume (30 Days)
- MFIN 35.3K
- GLSI 63.1K
- Earning Date
- MFIN 10-28-2025
- GLSI 11-13-2025
- Dividend Yield
- MFIN 4.58%
- GLSI N/A
- EPS Growth
- MFIN N/A
- GLSI N/A
- EPS
- MFIN 1.75
- GLSI N/A
- Revenue
- MFIN $332,256,000.00
- GLSI N/A
- Revenue This Year
- MFIN N/A
- GLSI N/A
- Revenue Next Year
- MFIN $1.53
- GLSI N/A
- P/E Ratio
- MFIN $5.98
- GLSI N/A
- Revenue Growth
- MFIN 16.48
- GLSI N/A
- 52 Week Low
- MFIN $7.52
- GLSI $8.06
- 52 Week High
- MFIN $10.98
- GLSI $15.50
- Technical
- Relative Strength Index (RSI)
- MFIN 46.96
- GLSI 45.94
- Support Level
- MFIN $10.44
- GLSI $11.12
- Resistance Level
- MFIN $10.87
- GLSI $11.90
- Average True Range (ATR)
- MFIN 0.23
- GLSI 0.70
- MACD
- MFIN -0.05
- GLSI -0.03
- Stochastic Oscillator
- MFIN 10.00
- GLSI 23.24
About MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. The five operating segments are, (1) recreation, (2) home improvement, (3) commercial, (4) taxi medallion, and (5) strategic partnership loans. The company generates maximum revenue from the Recreation segment.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.